

Poor Hemorrhagic Stroke Outcomes During the COVID-19 Pandemic Are Driven by Socioeconomic Disparities: Analysis of Nationally Representative Data

Short Title: Effect of COVID-19 on Stroke Hemorrhagic Outcomes

Abdulaziz T. Bako MBBS MPH PhD¹; Thomas Potter PhD,¹ Alan Pan MS,² Karim A. Borei MD MBBCh,¹ Taya Prince BS,¹ Gavin Britz MD MPH,¹ Farhaan S. Vahidy PhD MBBS MPH;^{1,2,3}*

1. Department of Neurosurgery, Houston Methodist, Houston, TX.
2. Center for Health Data Science and Analytics, Houston Methodist, Houston, TX
3. Department of Population Health Sciences, Weill Cornell Medical College, New York, NY

Corresponding Author:

Abdulaziz T. Bako, PhD MBBS MPH

7550 Greenbriar Drive, Suite 4.73

Houston, TX 77030

atbako@houstonmethoist.org

Conflict of Interest: The authors declare no conflict of interest

Keywords: Intracerebral Hemorrhage, Subarachnoid Hemorrhage, COVID-19, Socioeconomic Disparities, Social Determinants of Health.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Abstract

Background

Nationally representative data demonstrating the impact of the COVID-19 pandemic on hemorrhagic stroke outcomes are lacking.

Methods

In this pooled cross-sectional analysis, we used the National Inpatient Sample (2016-2020) to identify adults (≥ 18 years) with primary intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH). We fit segmented logistic regression models to evaluate the differences in the rates of in-hospital outcomes (in-hospital mortality, home discharge, and receiving neurosurgical procedures) between the pre-pandemic (January 2016-February 2020) and pandemic periods (March 2020-December 2020). We used multivariable logistic regression models to evaluate the differences in mortality between patients admitted from April to December 2020, with and without COVID-19, and those admitted during a similar period in 2019. Stratified analyses were conducted among patients residing in low and high-income zip codes and among patients with extreme loss of function (E-LoF) and those with minor to major loss of function (MM-LoF).

Results

Overall, 309,965 ICH patients (mean age [SD]: 68[14.8], 47% female, 56% low-income) and 112,210 SAH patients (mean age [SD]: 60.2[15.4], 62% female, 55% low-income) were analyzed. Pre-pandemic, ICH mortality was decreasing by $\approx 1\%$ per month (adjusted odds ratio, 95% confidence interval: 0.99, 0.99-1.00). However, during the pandemic, the overall ICH mortality rate increased by $\approx 2\%$ per month (1.02, 1.00-1.02) and $\approx 4\%$ per month among low-income patients (1.04, 1.01-1.07). However, there was no change in trend among high-income ICH patients during the pandemic (1.00, 0.97-1.03). Patients with comorbid COVID-19 in 2020 had significantly higher odds of mortality compared to the 2019 comparison cohort, overall (ICH: 1.83, 1.33-2.51; SAH: 2.76, 1.68-4.54), and among patients with MM-LoF (ICH: 2.15, 1.12-4.16; SAH: 5.77, 1.57-21.17). However, patients with E-LoF and comorbid COVID-19 had similar mortality rates with the 2019 cohort.

31 **Conclusion**

32 Sustained efforts are needed to address socioeconomic disparities in healthcare
33 access, quality, and outcomes during public health emergencies.

34

35 **Introduction**

36 The global outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2,
37 resulted in a pandemic that disrupted healthcare, especially among vulnerable
38 populations.^{1,2} COVID-19 infection may worsen vascular diseases by disrupting the
39 coagulation cascade and exacerbating inflammatory responses.^{3,4} Although prior
40 studies have shown that COVID-19 increases the risk of poor outcomes among patients
41 with ischemic stroke,^{5,6} there is a paucity of nationally representative data on the
42 potential impact of the COVID-19 pandemic on the trends in hemorrhagic stroke
43 (intracerebral hemorrhage [ICH] and subarachnoid hemorrhage [SAH]) outcomes.
44 Therefore, we used the largest publicly available all-payer inpatient healthcare database
45 in the United States (US), the National Inpatient Sample (NIS), to evaluate the
46 differences in the trends of hemorrhagic stroke outcomes before and after the COVID-
47 19 pandemic.

48 **Methods**

49 *Ethics Statement*

50 Because this research utilized publicly available and de-identified data, it is considered
51 exempt from review by the Houston Methodist Institutional Review Board. We followed
52 the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)
53 guidelines.⁷

54 *Data availability*

55 After completing a data use agreement training, qualified researchers can obtain NIS
56 data through the Health Care Utilization Project's central distributor
57 (<https://www.distributor.hcup-us.ahrq.gov/>).

58 *Study Design, Data Source, and Case Identification*

59 NIS represents over 90% of all US hospitalizations.⁸ In this pooled cross-sectional
60 study, we used validated International Classification of Disease Tenth Revision (ICD-10)
61 codes to identify adults (≥ 18 years) discharged with a principal diagnosis of ICH (ICD-

62 10 codes: I61.0-I61.6 and I61.8-I61.9) or SAH (I60) from 2016 to 2020. We excluded
63 patients with concurrent diagnoses of head trauma and/or arteriovenous malformation,
64 as well as patients with missing age information. Also, we excluded patients transferred
65 to an acute care hospital to avoid double counting the same patient, as the unit of
66 observation in the NIS database is a hospitalization encounter and not an individual
67 patient. Among the ICH cohort, we additionally excluded patients with co-occurring
68 diagnoses of intracranial aneurysms and brain malignancy.

69 Race/ethnicity was coded as non-Hispanic White (NHW), non-Hispanic Black (NHB),
70 Asian American and Pacific Islanders (AAPI), Hispanic, and Others (including Native
71 Americans and Others). Income status was defined according to the income quartile of
72 the patient's zip code, with quartiles 1 and 2 considered as low-income and quartiles 3
73 and 4 considered as high-income zip codes. The National Institutes of Health Stroke
74 Scale (NIHSS) score was only available for less than one-third (20.7%) of our analysis
75 sample; therefore, we utilized the administratively derived All Patient Refined Diagnosis
76 Related Group (APR-DRG) severity of illness scores to assess disease severity. We
77 further grouped patients, based on their APR-DRG severity of illness score, into those
78 with extreme loss of function (E-LoF) and those with minor to major loss of function
79 (MM-LoF).⁹ COVID-19 status was identified using ICD-10 code U07.1. This ICD code
80 was released in late March of 2020 and is reserved for laboratory-confirmed cases of
81 SARS-CoV-2.

82 The primary outcome is in-hospital mortality and secondary outcomes include home
83 discharge, receiving craniotomy (for ICH cohort), and undergoing coiling or clipping (for
84 SAH cohort).

85 *Statistical Analyses*

86 Descriptive statistics were reported using means and percentages. We used a series of
87 univariable logistic regression models to evaluate the differences in the clinical and
88 sociodemographic characteristics of patients admitted before the official declaration of
89 national emergency response to the COVID-19 pandemic (January 2016 - February
90 2020) (pre-pandemic period), and patients admitted during and after the emergency
91 declaration (March 2020 – December 2020) (pandemic period). Furthermore, we fit a

92 series of unadjusted and adjusted segmented logistic regression models¹⁰ (details in
93 supplemental methods) to evaluate the differences in the rates (slope) of in-hospital
94 outcomes between the pre-pandemic and pandemic periods, as crude/adjusted odds
95 ratios (OR/aOR) and 95% confidence interval (CI). The multivariable models included
96 adjustments for sociodemographic factors (age, sex, race/ethnicity, and insurance type),
97 clinical factors (hypertension, diabetes, congestive heart failure, obesity, renal failure,
98 Charlson Comorbidity Index, and APR-DRG severity of illness score), and hospital-
99 related factors (urban/rural location of hospital, teaching status of hospital, and hospital
100 bed size). To evaluate whether income modifies the association of the pandemic with
101 ICH and SAH outcomes, we performed stratified analyses among patients residing in
102 low-income and high-income zip codes.

103 In a second series of analyses, we used multivariable logistic regression models to
104 evaluate the sociodemographic and clinical factors independently associated with
105 having comorbid COVID-19 infection and ICH or SAH among a cohort of patients
106 admitted April to December 2020. In a third and final series of analyses, we used
107 multivariable logistic regression models to assess the differences in mortality, between
108 ICH and SAH patients admitted from April to December 2020, with and without COVID-
109 19, and patients admitted during a similar period in 2019. We performed stratified
110 multivariable analyses among patients with MM-LoF and those with E-LoF. The
111 confounding variables in all adjusted models were selected based on prior evidence
112 demonstrating their association with hemorrhagic stroke outcomes. All analyses were
113 conducted with 0.05 level of significance, utilizing Stata version 17.¹¹.

114 **Results**

115 Overall, 309,965 ICH patients (mean age [SD]: 68 [14.8], 47% female, 56% residing in
116 low-income zip codes) and 112,210 SAH patients (mean age [SD]: 60.2 [15.4], 62%
117 female, 55% residing in low-income zip codes) were included (Table S1). Among the
118 ICH cohort, 259,535 patients (mean age [SD]: 68 [14.8], 47% female, 55% residing in
119 low-income zip codes) were admitted during the pre-pandemic period and 50,430
120 patients (mean age [SD]: 67 [14.9], 46% female, 57% residing in low-income zip codes)
121 were admitted during the pandemic period. Among the SAH cohort, 93,855 patients

122 (mean age [SD]: 60.2 [15.4], 62% female, 56% residing in low-income zip codes) were
123 admitted during the pre-pandemic period and 18,355 patients (mean age [SD]: 60.1
124 [15.3], 60% female, 57% residing in low-income zip codes) were admitted during the
125 pandemic period. In univariate analyses, ICH patients admitted during the pandemic
126 period were significantly more likely to be insured via Medicaid (OR, 95% CI: 1.23, 1.14
127 – 1.33) or private (1.08, 1.01 – 1.15) insurance (vs. Medicare), have heart failure (1.13,
128 1.06 – 1.20), obesity (1.30, 1.21 – 1.39), renal failure (1.07, 1.01 – 1.13) and higher
129 Charlson Comorbidity Index (1.03, 1.02 – 1.04) (Table S1).

130 In the pre-pandemic period, the mortality rate among ICH patients was decreasing by
131 approximately 1% per month (aOR, 95% CI: 0.99, 0.99 – 1.00; p-value < 0.001).
132 However, the overall mortality rate during the pandemic period increased by about 2%
133 per month relative to the monthly rate in the pre-pandemic period (1.02, 1.00 – 1.02, p-
134 value < 0.05) (See figure 1A and Table 1). Among patients residing in low-income zip
135 codes, mortality rate during the pandemic period increased by 4% per month relative to
136 the pre-pandemic period (1.04, 1.01 – 1.07). However, there was no significant change
137 in mortality trend during the pandemic period among ICH patients residing in high-
138 income zip codes (1.00, 0.97 – 1.03) (Table 1 and Figure 1B and 1C). Also, there was
139 no significant change in the trend for other ICH outcomes or any SAH outcomes during
140 the pandemic period (vs. pre-pandemic).

141 Among patients admitted between April and December 2020 (ICH: 44,405 without
142 COVID-19 and 935 with COVID-19; SAH: 16,205 without COVID-19 and 395 with
143 COVID-19), males (aOR, 95% CI: 1.42, 1.03 – 1.97) (vs. females), NHB (1.94, 1.28 –
144 2.95), Hispanics (3.59, 2.29 – 5.64) and the “Other” race/ethnicity category (3.66, 2.16 –
145 6.19) (vs. NHW) had significantly higher odds of having comorbid ICH and COVID-19,
146 while Hispanics (vs. NHW) have significantly higher odds of having comorbid SAH and
147 COVID-19 (4.73, 2.88 – 7.79) (Figure 2).

148 In multivariable analyses, ICH and SAH patients with comorbid COVID-19 had a
149 significantly higher likelihood of mortality compared to patients admitted between April
150 to December 2019, overall (aOR, 95% CI: 1.83, 1.33 – 2.51 for ICH; and 2.76, 1.68 –
151 4.54 for SAH) and among patients with MM-LoF (2.15, 1.12 – 4.16 for ICH; and 5.77,

152 1.57 – 21.17 for SAH). However, among patients with E-LoF, there was no significant
153 difference in the likelihood of mortality between ICH and SAH patients with comorbid
154 COVID-19 admitted between April to December 2020 and patients admitted during a
155 similar period in 2019. Furthermore, among ICH and SAH patients without comorbid
156 COVID-19, the likelihood of mortality was similar across the 2020 and 2019 April to
157 December cohorts.

158 Tables S2 and S3 provide details of the univariate comparisons of the characteristics of
159 ICH and SAH patients with comorbid COVID-19 (admitted between April to December
160 2020) and patients admitted during a similar period in 2019 (model group 1). Tables S2
161 and S3 also provide univariate comparisons of ICH and SAH patients admitted between
162 April and December 2020 with and without comorbid COVID-19 (model group 2).

163 **Discussion**

164 We evaluated the association of the COVID-19 pandemic with ICH and SAH in-hospital
165 outcomes in a nationally representative sample. Relative to the pre-pandemic period,
166 we observed a significant increase in the monthly rate of in-hospital mortality among
167 ICH patients during the pandemic period. This increase was primarily driven by ICH
168 patients residing in low-income zip codes, whereas no change in mortality was
169 observed among patients residing in high-income zip codes. We also demonstrate that
170 comorbid COVID-19 was associated with higher likelihood of mortality among ICH and
171 SAH patients with MM-LoF, but not among patients with E-LoF.

172 Similar to a previous report,¹² our analyses demonstrate that ICH mortality was
173 significantly declining during the pre-pandemic period. However, this trend was reversed
174 during the pandemic period, particularly among patients residing in low-income zip
175 codes. Relative to the pre-pandemic period, the overall ICH mortality rate increased by
176 2% per month in the pandemic period. This acceleration of mortality rate seems to be
177 largely driven by patients residing in low-income zip codes, among whom ICH mortality
178 rate increased by 4% per month during the pandemic period, whereas no significant
179 change in mortality was observed among patients residing in high-income zip codes
180 during the pandemic period. These findings suggest that the COVID-19 pandemic may
181 have slowed down the sustained improvement in ICH mortality observed during the pre-

182 pandemic period, particularly among the low-income population. Though our analyses
183 do not definitively outline the reasons for disparate COVID-19 associated ICH
184 outcomes; higher comorbidity burden, lack of access, awareness, and even disparities
185 in care (including delayed care) may be postulated as potential drivers of such
186 disparities. Most importantly, our analyses are yet another demonstration of the
187 pandemic's disproportionate impact on vulnerable populations and highlight the need for
188 continued focus on uncovering and addressing the reasons for the now widely reported
189 socioeconomic disparities, particularly among patients with cerebrovascular disease .¹³

190 Similar to prior smaller studies, we also report that hemorrhagic stroke (ICH and SAH)
191 patients with comorbid COVID-19 have significantly higher mortality compared to
192 patients without COVID-19.^{14,15} However, our data uniquely demonstrates, at the
193 national level, that comorbid COVID-19 was only associated with a higher likelihood of
194 in-hospital mortality among ICH and SAH patients with MM-LoF, whereas among
195 patients with E-LoF, COVID-19 status was not a significant driver of mortality. These
196 findings have significant clinical relevance, and though we are limited from conducting a
197 clinically detailed exploration of the biological mechanisms driving the differences in
198 mortality between hemorrhagic stroke patients with and without comorbid COVID-19, it
199 is reasonable to surmise, from previous studies, that a heightened systematic
200 inflammatory response to the COVID-19 virus and its directed end organ damage may
201 be potentiating these poor outcomes.¹⁶ However, further studies are needed to
202 elucidate the mechanisms driving poorer outcomes among hemorrhagic stroke patients
203 with comorbid COVID-19. Also, given that minority races/ethnicities are at a higher
204 likelihood of having comorbid COVID-19, the findings of this research highlight the need
205 to further investigate the biological and environmental factors potentially driving
206 socioeconomic disparities in the association between COVID-19 and hemorrhagic
207 stroke outcomes.

208 Our study has some limitations. First, this study covers only the first wave of the
209 COVID-19 pandemic. Hence, future studies are needed to explore the trends in the
210 subsequent waves of the pandemic as data for ensuing years become available.
211 Secondly, our analysis may have missed COVID-19 patients who did not require or

212 receive in-hospital care for COVID-19 and potentially underestimated the prevalence of
213 COVID-19 among patients with ICH and SAH. Thirdly, we did not have detailed data on
214 the timing of hemorrhagic stroke and COVID-19 diagnosis. Finally, we did not have
215 access to more granular clinical data, including patients' imaging data (to ascertain
216 hemorrhage location, volume, or other hemorrhage characteristics) and information on
217 the COVID-19 variants. Nevertheless, the insights provided by this study will be useful
218 in guiding the readiness of public health authorities to implement strategies addressing
219 sociodemographic disparities during public health emergencies.

220 **Conclusions**

221 The study found a significant acceleration of in-hospital mortality rate among ICH
222 patients during the post-pandemic period, particularly among those residing in low-
223 income zip codes. Sustained efforts are needed to better understand the impact of the
224 pandemic on stroke outcomes, particularly among vulnerable populations, as well as to
225 address disparities in healthcare access, quality, and outcomes during public health
226 emergencies.

227 **Acknowledgments**

228 Dr Bako had full access to all the data in the study and takes responsibility for the
229 integrity of the data and the accuracy of the data analysis. The content of this article is
230 based on data from the National Inpatient Sample (NIS) database, acquired from the
231 Agency for Healthcare Research and Quality's (AHRQ) Health Care Utilization Project
232 (HCUP). However, the content of this article does not necessarily reflect the views and
233 opinions of the AHRQ. Also, the AHRQ did not participate in the study's design,
234 implementation, data analysis, interpretation, nor manuscript preparation, review,
235 approval, or decision to submit the article for publication.

236 **Disclosures**

237 Authors declare no conflict of interest.

238

239 **Figure 1: Segmented logistic regression of the effect of the COVID-19 pandemic on**
240 **Intracerebral Hemorrhage Mortality, Overall (A) and disaggregated by low (B)**
241 **and high (C) income residence status**

242

243

244 Segmented logistic regression of the effect of the COVID-19 pandemic on Intracerebral Hemorrhage Mortality — unadjusted.

245 The solid lines run through pre-intervention and post-intervention unexponentiated coefficients (logit), while the dotted lines
246 represent what the post-pandemic trend would have been had the pandemic not occurred (counterfactual). The coefficients
247 used for this plot have not been adjusted for confounding variables; however, the reported p-values for the difference in slope
248 between pre-pandemic and post-pandemic period have been adjusted for confounding. A p-value < 0.05 indicates that there is
249 a significant change in trend (slope) between the pre-pandemic and post-pandemic mortality rate.

250

251 **Figure 2: Sociodemographic factors associated with having comorbid COVID-19 and ICH/SAH**

252

253

254

255 **Table 1: Effect of the COVID-19 Pandemic on ICH and SAH Mortality**

Adjusted Models		
	ICH Mortality	SAH Mortality
Overall		
Pre-Covid Slope	0.99 (0.99 – 1.00) ***	1.00 (0.99 – 1.00) *
Post-Covid Slope	1.02 (1.00 – 1.04)	0.99 (0.96 – 1.02)
Difference between Pre- and Post-Covid Slope	1.02 (1.00 – 1.04) *	0.99 (0.96 – 1.03)
Low Income		
Pre-Covid Slope	1.00 (0.99 – 1.00) ***	1.00 (0.99 – 1.00)
Post-Covid Slope	1.04 (1.01 – 1.06) **	0.99 (0.95 – 1.03)
Difference between Pre- and Post-Covid Slope	1.04 (1.01 – 1.07) **	0.99 (0.95 – 1.04)
High Income		
Pre-Covid Slope	0.99 (0.99 – 1.00) ***	1.00 (0.99 – 1.00)
Post-Covid Slope	0.99 (0.96 – 1.02)	0.98 (0.93 – 1.03)
Difference between Pre- and Post-Covid Slope	1.00 (0.97 – 1.03)	0.99 (0.94 – 1.04)
Unadjusted Models		
	ICH Mortality	ICH Mortality
Overall		
Pre-Covid Slope	1.00 (1.00 – 1.00) ***	1.00 (0.99 – 1.00) *
Post-Covid Slope	1.01 (1.00 – 1.03)	1.00 (0.98 – 1.03)
Difference between Pre- and Post-Covid Slope	1.02 (1.00 – 1.03)	1.01 (0.98 – 1.03)
Low Income		
Pre-Covid Slope	1.00 (0.99 – 1.00) **	1.00 (0.99 – 1.00)
Post-Covid Slope	1.02 (1.00 – 1.05) *	1.00 (0.97 – 1.04)
Difference between Pre- and Post-Covid Slope	1.03 (1.01 – 1.05) *	1.01 (0.97 – 1.04)
High Income		
Pre-Covid Slope	1.00 (0.99 – 1.00) **	1.00 (0.99 – 1.00)
Post-Covid Slope	1.00 (0.97 – 1.02)	0.99 (0.95 – 1.04)
Difference between Pre- and Post-Covid Slope	1.00 (0.98 – 1.02)	1.00 (0.96 – 1.04)

256 * - p-value < 0.05; ** - p-value < 0.01; *** - p-value < 0.001

257 **References**

- 258 1. Pujolar G, Oliver-Anglès A, Vargas I, Vázquez M-L. Changes in access to health
259 services during the COVID-19 pandemic: A scoping review. *Int. J. Environ. Res.*
260 *Public Health.* 2022;19:1749.
- 261 2. Tannous J, Pan A, Bako A, Potter T, Jones SL, Janjan N, Smith ML, Seshadri S,
262 Ory MG, Vahidy FS. COVID-19 associated disruptions in routine health care of
263 people with mild cognitive impairment or dementia. *Alzheimers. Dement.* [Internet].
264 2022;14. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/dad2.12323>
- 265 3. Vidal-Perez R, Brandão M, Pazdernik M, Kresoja K-P, Carpenito M, Maeda S,
266 Casado-Arroyo R, Muscoli S, Pöss J, Fontes-Carvalho R, et al. Cardiovascular
267 disease and COVID-19, a deadly combination: A review about direct and indirect
268 impact of a pandemic. *World J. Clin. Cases.* 2022;10:9556–9572.
- 269 4. Vasbinder A, Meloche C, Azam TU, Anderson E, Catalan T, Shadid H, Berlin H,
270 Pan M, O’Hayer P, Padalia K, et al. Relationship between preexisting
271 cardiovascular disease and death and cardiovascular outcomes in critically ill
272 patients with COVID-19. *Circ. Cardiovasc. Qual. Outcomes.* 2022;15:e008942.
- 273 5. de Havenon A, Zhou LW, Yaghi S, Frontera JA, Sheth KN. Effect of COVID-19 on
274 acute ischemic stroke severity and mortality in 2020: Results from the 2020
275 National Inpatient Sample. *Stroke.* 2023;54:e194–e198.
- 276 6. Qureshi AI, Baskett WI, Huang W, Shyu D, Myers D, Raju M, Lobanova I, Suri
277 MFK, Naqvi SH, French BR, et al. Acute ischemic stroke and COVID-19: An
278 analysis of 27 676 patients. *Stroke.* 2021;52:905–912.
- 279 7. Cuschieri S. The STROBE guidelines. *Saudi J. Anaesth.* 2019;13:S31–S34.
- 280 8. NIS Database Documentation [Internet]. The Healthcare Cost and Utilization
281 Project. [cited 2023 Feb 2]; Available from: [https://www.hcup-](https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp)
282 [us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp](https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp)
- 283 9. Averill RF, Goldfield N, Hughes JS, Bonazelli J, McCullough EC, Steinbeck BA,
284 Mullin R, Tang AM. ALL PATIENT REFINED DIAGNOSIS RELATED GROUPS
285 (APR-DRGs) [Internet]. 07/2023 [cited 2023 Jun 15]; Available from: [https://hcup-](https://hcup-us.ahrq.gov/db/nation/nis/APR-DRGsV20MethodologyOverviewandBibliography.pdf)
286 [us.ahrq.gov/db/nation/nis/APR-](https://hcup-us.ahrq.gov/db/nation/nis/APR-DRGsV20MethodologyOverviewandBibliography.pdf)
287 [DRGsV20MethodologyOverviewandBibliography.pdf](https://hcup-us.ahrq.gov/db/nation/nis/APR-DRGsV20MethodologyOverviewandBibliography.pdf)
- 288 10. Mascha EJ, Sessler DI. Segmented regression and difference-in-difference
289 methods: Assessing the impact of systemic changes in health care. *Anesth. Analg.*
290 2019;129:618–633.
- 291 11. Statacorp. Stata Statistical Software: Release 17 [Internet]. College Station, TX:
292 StataCorp LLC.; 2021. Available from: <https://www.stata.com/>

- 293 12. Bako AT, Potter T, Pan A, Tannous J, Rahman O, Langefeld C, Woo D, Britz G,
294 Vahidy FS. Geographic disparities in case fatality and discharge disposition among
295 patients with primary intracerebral hemorrhage. *J. Am. Heart Assoc.*
296 2023;12:e027403.
- 297 13. Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic
298 review of racial/ethnic and socioeconomic disparities in COVID-19. *Int. J. Equity*
299 *Health.* 2021;20:248.
- 300 14. Ravindra VM, Grandhi R, Delic A, Hohmann S, Shippey E, Tirschwell D, Frontera
301 JA, Yaghi S, Majersik JJ, Anadani M, et al. Impact of COVID-19 on the
302 hospitalization, treatment, and outcomes of intracerebral and subarachnoid
303 hemorrhage in the United States. *PLoS One.* 2021;16:e0248728.
- 304 15. Leasure AC, Khan YM, Iyer R, Elkind MSV, Sansing LH, Falcone GJ, Sheth KN.
305 Intracerebral hemorrhage in patients with COVID-19: An analysis from the COVID-
306 19 cardiovascular disease registry. *Stroke.* 2021;52:e321–e323.
- 307 16. Mitra J, Kodavati M, Provasek VE, Rao KS, Mitra S, Hamilton DJ, Horner PJ,
308 Vahidy FS, Britz GW, Kent TA, et al. SARS-CoV-2 and the central nervous system:
309 Emerging insights into hemorrhage-associated neurological consequences and
310 therapeutic considerations. *Ageing Res. Rev.* 2022;80:101687.







